These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8928519)

  • 1. [ACE inhibitors from the viewpoint of the clinical pharmacologist].
    Hitzenberger G
    Wien Med Wochenschr; 1996; 146(11):225-7. PubMed ID: 8928519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the renin--angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function.
    Neutel JM
    J Hum Hypertens; 2004 Sep; 18(9):599-606. PubMed ID: 15190263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ACE inhibitor. Effective blood pressure control around the clock].
    MMW Fortschr Med; 2001 Sep; 143(35-36):60. PubMed ID: 11584537
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rationale for treatment of endothelial dysfunction in hypertension.
    Ruschitzka F; Corti R; Noll G; Lüscher TF
    J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the renin-angiotensin system in vascular health: use of ACE inhibition to improve vascular function.
    Izzo JL
    Heart Dis; 2000; 2(5):380-3. PubMed ID: 11728286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardioactive hormones: bradykinin].
    Dendorfer A; Simon M; Dominiak P
    Z Kardiol; 1996; 85 Suppl 6():211-8. PubMed ID: 9064968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme.
    Hirota T; Ohki K; Kawagishi R; Kajimoto Y; Mizuno S; Nakamura Y; Kitakaze M
    Hypertens Res; 2007 Jun; 30(6):489-96. PubMed ID: 17664851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.
    White CM
    Pharmacotherapy; 1998; 18(3):588-99. PubMed ID: 9620109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
    Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial dysfunction: its pathogenic role in atherosclerosis and its reversal by ACE inhibition.
    Neutel JM
    Postgrad Med; 2000 Oct; 108(5 Suppl):4-11. PubMed ID: 19667535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of endothelial enzymes: new therapeutic targets.
    López-Jaramillo P; Casas JP
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S100-3. PubMed ID: 11986905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors.
    Goto K; Fujii K; Kansui Y; Iida M
    Clin Exp Pharmacol Physiol; 2004 Sep; 31(9):650-5. PubMed ID: 15479174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients.
    Yavuz D; Koç M; Toprak A; Akpinar I; Velioğlu A; Deyneli O; Haklar G; Akalin S
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):197-203. PubMed ID: 14608527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistance to ACE inhibitors. Myth or reality?].
    Aumont MC; Juliard JM
    Arch Mal Coeur Vaiss; 2001 Sep; 94(9):1008-12. PubMed ID: 11603063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension.
    Pronko TP; Zinchuk VV
    Clin Physiol Funct Imaging; 2009 May; 29(3):170-6. PubMed ID: 19170724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.